[{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by TRACON Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target